CXF vs. FRX, IPA, CRDL, APM, GXE, ITH, GPH, MDNA, EQ, and WMD
Should you be buying CI Canadian Convertible Bond ETF Common stock or one of its competitors? The main competitors of CI Canadian Convertible Bond ETF Common include Fennec Pharmaceuticals (FRX), ImmunoPrecise Antibodies (IPA), Cardiol Therapeutics (CRDL), Andean Precious Metals (APM), Gear Energy (GXE), International Tower Hill Mines (ITH), Graphite One (GPH), Medicenna Therapeutics (MDNA), EQ (EQ), and WeedMD (WMD). These companies are all part of the "pharmaceutical products" industry.
CI Canadian Convertible Bond ETF Common vs.
Fennec Pharmaceuticals (TSE:FRX) and CI Canadian Convertible Bond ETF Common (TSE:CXF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than CI Canadian Convertible Bond ETF Common. MarketBeat recorded 1 mentions for Fennec Pharmaceuticals and 0 mentions for CI Canadian Convertible Bond ETF Common. Fennec Pharmaceuticals' average media sentiment score of 0.70 beat CI Canadian Convertible Bond ETF Common's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
CI Canadian Convertible Bond ETF Common has lower revenue, but higher earnings than Fennec Pharmaceuticals.
CI Canadian Convertible Bond ETF Common has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of 29.94% beat CI Canadian Convertible Bond ETF Common's return on equity.
52.8% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Fennec Pharmaceuticals received 93 more outperform votes than CI Canadian Convertible Bond ETF Common when rated by MarketBeat users. Likewise, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 57.89% of users gave CI Canadian Convertible Bond ETF Common an outperform vote.
Summary
Fennec Pharmaceuticals beats CI Canadian Convertible Bond ETF Common on 11 of the 12 factors compared between the two stocks.
Get CI Canadian Convertible Bond ETF Common News Delivered to You Automatically
Sign up to receive the latest news and ratings for CXF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CI Canadian Convertible Bond ETF Common Competitors List
Related Companies and Tools
This page (TSE:CXF) was last updated on 2/22/2025 by MarketBeat.com Staff
